Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06378749 · ClinicalTrials.gov registry record · NA

Previvors Recharge: A Resilience Program for Cancer Previvors

A NA study, sponsored by Pro-Change Behavior Systems.

Completed
Registry status
NA
Development phase
138
Enrollment target

NCT06378749: Completed NA study, sponsored by Pro-Change Behavior Systems.

NCT06378749 is a NA study that has completed, run by Pro-Change Behavior Systems. The registered enrollment target is 138 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06378749, a NA study, has completed, sponsored by Pro-Change Behavior Systems.

COMPLETED
Registry status
NA
Development phase
138 participants
Enrollment target

Study Summary

It is estimated that 1 in 279 people may be carriers of a Hereditary Cancer Syndromes (HCS), a cancer risk that is associated with germline mutations (inherited genetic mutations passed directly from a parent to a child that create a genetic predisposition to certain types of cancer). Individuals with an HCS who have never been diagnosed with cancer (Previvors) have up to an 80% lifetime risk of developing cancer and are at an increased risk of developing multiple primary cancers during their lifetime, often with onset at an early age. Previvors face multiple forms of adversity, including a multitude of annual cancer screenings and the uncertainty of not only their own health but the health of affected family members. This study will examine the acceptability and preliminary effects of PreCharge, a resilience-boosting solution specifically designed for Previvors and delivered primarily via bi-directional text messaging. PreCharge uses proven approaches to behavior change tailoring to increase resilience by promoting a positive mindset, strong social connections, and a deep sense of meaning and purpose while also proactively addressing scanxiety. Up to 150 Hereditary Cancer Previvors will be recruited for a 30-day pilot test. Participants will complete a baseline assessment, and then be provided with 30 days of access to the PreCharge program. At the end of the 30 days, they will be prompted to complete a follow-up assessment. Outcomes to be examined will include pre-post changes on the Connor Davidson Resilience Scale.

Primary Outcome

This 10-item scale assesses five factors related to resilience. Each item is rated on a 5-point scale with higher scores reflecting greater resilience. Scores range from 0-40. There are well-established norms across a variety of populations and the scale has been used as an outcome measure to evaluate a variety of different intervention programs.

Interventions

  • BEHAVIORAL PreCharge

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2024-04-11
Est. Completion 2024-09-27
Phase NA
Pro-Change Behavior Systems

11 total trials

What the finished NCT06378749 record still lists

NCT06378749 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 1 intervention - of which PreCharge is the first listed.

NCT06378749 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06378749 about?

NCT06378749 is a clinical study titled "Previvors Recharge: A Resilience Program for Cancer Previvors". It is estimated that 1 in 279 people may be carriers of a Hereditary Cancer Syndromes (HCS), a cancer risk that is associated with germline mutations (inherited genetic mutations passed directly from a parent to a child that create a genetic predisposition to certain types of cancer). Individuals wi...

What is the current status of trial NCT06378749?

This trial is currently completed. It is a NA study. The enrollment target is 138 participants. The study started on 2024-04-11. Estimated completion is 2024-09-27.

What interventions are being tested in trial NCT06378749?

The interventions under investigation include: PreCharge (BEHAVIORAL).

Who is sponsoring clinical trial NCT06378749?

This trial is sponsored by Pro-Change Behavior Systems, which has 11 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06378749's enrollment target sits among peer trials

138 720th of 2000 higher than 1,279 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04402788 · 138 participants · Phase 2

    Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  • NCT04883255 · 138 participants · Early Phase 1

    Cannabis Use, Cognition, and the Endocannabinoid System in HIV

  • NCT05620784 · 138 participants · Phase 3

    Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

  • NCT05832086 · 138 participants · Phase 2

    Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06378749, the US trial registry maintained by the National Library of Medicine. NCT06378749 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.